BAUSCH HEALTH COS INC (BHC.CA) Stock Price & Overview

TSX:BHC • CA0717341071

Current stock price

6.82 CAD
-0.07 (-1.02%)
Last:

The current stock price of BHC.CA is 6.82 CAD. Today BHC.CA is down by -1.02%. In the past month the price decreased by -14.32%. In the past year, price decreased by -33.59%.

BHC.CA Key Statistics

52-Week Range5.91 - 11.97
Current BHC.CA stock price positioned within its 52-week range.
1-Month Range6.77 - 8.665
Current BHC.CA stock price positioned within its 1-month range.
Market Cap
2.527B
P/E
1.32
Fwd P/E
1.14
EPS (TTM)
5.17
Dividend Yield
N/A

BHC.CA Stock Performance

Today
-1.02%
1 Week
-6.96%
1 Month
-14.32%
3 Months
-28.44%
Longer-term
6 Months -32.21%
1 Year -33.59%
2 Years -52.47%
3 Years -37.72%
5 Years -82.89%
10 Years N/A

BHC.CA Stock Chart

BAUSCH HEALTH COS INC / BHC Daily stock chart

BHC.CA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BHC.CA. When comparing the yearly performance of all stocks, BHC.CA is a bad performer in the overall market: 95.1% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BHC.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BHC.CA. While BHC.CA is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BHC.CA Earnings

On February 20, 2026 BHC.CA reported an EPS of 1.1 and a revenue of 2.80B. The company missed EPS expectations (-13.87% surprise) and beat revenue expectations (2.23% surprise).

Next Earnings DateApr 28, 2026
Last Earnings DateFeb 20, 2026
PeriodQ4 / 2025
EPS Reported$1.10
Revenue Reported2.796B
EPS Surprise -13.87%
Revenue Surprise 2.23%

BHC.CA Forecast & Estimates

9 analysts have analysed BHC.CA and the average price target is 10.2 CAD. This implies a price increase of 49.56% is expected in the next year compared to the current price of 6.82.

For the next year, analysts expect an EPS growth of 15.65% and a revenue growth 4.35% for BHC.CA


Analysts
Analysts48.89
Price Target10.2 (49.56%)
EPS Next Y15.65%
Revenue Next Year4.35%

BHC.CA Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

BHC.CA Financial Highlights

Over the last trailing twelve months BHC.CA reported a non-GAAP Earnings per Share(EPS) of 5.17.


Income Statements
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Industry RankSector Rank
PM (TTM) 1.53%
ROA 0.6%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-4.35%
Sales Q2Q%9.26%
EPS 1Y (TTM)0%
Revenue 1Y (TTM)6.66%

BHC.CA Ownership

Ownership
Inst Owners44.72%
Shares370.56M
Float322.60M
Ins Owners11.42%
Short Float %N/A
Short RatioN/A

BHC.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
CRON CRONOS GROUP INC38.861.304B
TLRY TILRAY BRANDS INC N/A1.105B
DHT-UN DRI HEALTHCARE TRUST7.33923.618M
GUD KNIGHT THERAPEUTICS INC127.15602.253M
WEED CANOPY GROWTH CORP N/A569.809M
CPH CIPHER PHARMACEUTICALS INC20.52427.232M
NGEN NERVGEN PHARMA CORP N/A402.7M
TSND TERRASCEND CORP N/A345.979M
HITI HIGH TIDE INC24.63298.826M
ACB AURORA CANNABIS INC58.17266.537M
OGI ORGANIGRAM GLOBAL INC28.6263.504M
RX BIOSYENT INC17.69180.236M

About BHC.CA

Company Profile

BHC logo image Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.

Company Info

IPO: 1994-09-20

BAUSCH HEALTH COS INC

2150 St. Elzear Blvd. West

Laval QUEBEC H7L 4A8 CA

CEO: Joseph C. Papa

Employees: 20700

BHC Company Website

BHC Investor Relations

Phone: 18003611448

BAUSCH HEALTH COS INC / BHC.CA FAQ

What does BAUSCH HEALTH COS INC do?

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. The company is headquartered in Laval, Quebec and currently employs 20,700 full-time employees. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.


Can you provide the latest stock price for BAUSCH HEALTH COS INC?

The current stock price of BHC.CA is 6.82 CAD. The price decreased by -1.02% in the last trading session.


What is the dividend status of BAUSCH HEALTH COS INC?

BHC.CA does not pay a dividend.


How is the ChartMill rating for BAUSCH HEALTH COS INC?

BHC.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


On which exchange is BHC.CA stock listed?

BHC.CA stock is listed on the Toronto Stock Exchange exchange.


What sector and industry does BAUSCH HEALTH COS INC belong to?

BAUSCH HEALTH COS INC (BHC.CA) operates in the Health Care sector and the Pharmaceuticals industry.